A painkiller licensed for chronic pain has weak evidence behind it

A painkiller licensed for chronic pain has weak evidence behind it
Image: Intellect (generated)

In short: Nefopam is a non-opioid painkiller licensed in the UK for chronic pain, yet national guidelines do not list it as a treatment option. Its evidence is limited and conflicting, and its side effects can be significant. Its mechanism is only partly understood. Here is what the studies show, and why prescribers weigh it so carefully.

Nefopam is a centrally acting, non-opioid analgesic. Its exact mechanism is not well understood, but it is known to slow the reabsorption of serotonin, noradrenaline and dopamine, and to affect certain ion channels in the brain and spinal cord. It is licensed for both acute and chronic pain, with a recommended starting dose of 30 to 60 mg three times a day, rising to a maximum of 90 mg three times a day. The evidence base is thin. Most studies concern short-term use after surgery, and that evidence is still limited and conflicting. For chronic pain, the evidence rests on several small studies. A 1986 study in rheumatoid arthritis found nefopam more effective than placebo for pain and morning stiffness, though it relied on subjective measures. A 1988 study in the same condition found no statistically significant improvement over placebo, with a high dropout rate, mainly due to side effects. In a 1989 comparison with flurbiprofen for osteoarthritic pain, no significant difference in effectiveness was found, but more side effects occurred with nefopam.

Side effects are the central concern. The most common are nausea and vomiting, drowsiness, low blood pressure and abdominal pain, with confusion and hallucinations more likely in older people. Anticholinergic effects such as dry mouth and urinary retention can occur. Overdose causes neurological and cardiovascular symptoms and can lead to coma. Combining it with monoamine oxidase inhibitors is contraindicated because of the risk of severe hypertension, and caution is advised with tricyclic antidepressants. Because of this, the NHS guidance is that nefopam appears no more potent than NSAIDs, carries a real risk of adverse reactions, and may be considered when alternatives are unsuitable or have not worked, or as add-on therapy. Progress should be checked regularly, and the drug stopped if benefit does not appear soon. The NICE chronic pain guidelines do not list it, and SIGN finds the evidence insufficient to make any recommendation.

Nefopam is a useful reminder that a licensed medicine is not the same as a well-proven one. Regulators can approve a drug on the basis of some evidence, while clinical guidelines weigh the overall balance of benefit and harm more strictly. For a patient, the practical question is whether the expected relief justifies the side effects, and that judgement is best made with a clinician who reviews progress regularly.

Opens the Intellect+ feed with this card first. Swipe up for the next one.

Sources

To cite this card, link to https://intellectplus.co.uk/app/health-nefopam.

How we source, check and correct cards: Editorial standards.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

Finding something worth knowing…